U.S. markets close in 1 hour 35 minutes

IMV Inc. (IMV)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.7700-0.0200 (-0.72%)
As of 2:23PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Continuation Wedge (Bullish)

Continuation Wedge (Bullish)

Previous Close2.7900
Open2.7700
Bid2.7600 x 1800
Ask2.7900 x 3200
Day's Range2.7500 - 2.8300
52 Week Range2.0000 - 6.8200
Volume48,550
Avg. Volume270,774
Market Cap186.01M
Beta (5Y Monthly)2.07
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Do Options Traders Know Something About IMV Stock We Don't?
    Zacks

    Do Options Traders Know Something About IMV Stock We Don't?

    Investors need to pay close attention to IMV stock based on the movements in the options market lately.

  • Is IMV (TSE:IMV) A Risky Investment?
    Simply Wall St.

    Is IMV (TSE:IMV) A Risky Investment?

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma Patients
    Benzinga

    IMV's Lead Candidate To Be Evaluated With Keytruda In Pretreated B-Cell Lymphoma Patients

    Following feedback from the FDA, IMV Inc (NASDAQ: IMV) has inked an agreement with Merck & Co (NYSE: MRK) to initiate a Phase 2B trial evaluating IMV's lead compound, maveropepimut-S (DPX-Survivac), in combination with Merck's Keytruda (pembrolizumab) in patients with recurrent/refractory diffuse large B cell lymphoma (r/rDLBCL). The contribution of low-dose cyclophosphamide (CPA) as an activator of immune response will also be evaluated in this trial. In a press release issued on March 17, the company announced that the FDA provided feedback on the clinical trial design. The study is expected to begin in Q2 2021. The three-arm Phase 2B trial is designed to assess the combination of maveropepimut-S and Keytruda with or without CPA. A third arm will evaluate maveropepimut-S as a single agent. Across the three arms of this study, IMV's lead compound will be evaluated in up to 150 subjects who have received at least two prior lines of systemic therapy and who are ineligible or have failed autologous stem cell transplant (ASCT) or CAR-T therapy. The primary endpoint is Objective Response Rate. Maveropepimut-S consists of survivin-based peptides designed to generate a sustained cytotoxic T cell response against cancer cells presenting survivin peptides on their surface. Price Action: MRK shares are up 0.3% at $76, while IMV shares are down 1.25% at $3.15 in the premarket session on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaEMA May Issue Updated Recommendation If AstraZeneca Jab-Clot Link Is Established: ReportPfizer-BioNTech's COVID-19 Vaccine Gives 100% Protection In Adolescents© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.